400 related articles for article (PubMed ID: 15816610)
1. Circulating hormone levels in breast cancer patients. correlation with serum tumor markers and the clinical and biological features of the tumors.
Hernández L; Nuñez-Villarl MJ; Martínez-Arribas F; Pollán M; Schneider J
Anticancer Res; 2005; 25(1B):451-4. PubMed ID: 15816610
[TBL] [Abstract][Full Text] [Related]
2. Circulating estradiol defines the tumor phenotype in menopausal breast cancer patients.
Schneider J; Martín-Gutiérrez S; Tresguerres JA; García-Velasco JA
Maturitas; 2009 Sep; 64(1):43-5. PubMed ID: 19647960
[TBL] [Abstract][Full Text] [Related]
3. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.
Martínez-Arribas F; Núñez-Villar MJ; Lucas AR; Sánchez J; Tejerina A; Schneider J
Anticancer Res; 2003; 23(1B):565-8. PubMed ID: 12680147
[TBL] [Abstract][Full Text] [Related]
4. Peptide and steroid hormone levels in pre- and postmenopausal breast carcinoma.
Bhatavdekar JM; Shah NG; Trivedi SN; Karelia NH
Neoplasma; 1987; 34(1):95-9. PubMed ID: 3104809
[TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer.
Molina R; Filella X; Zanon G; Pahisa J; Alicarte J; Munoz M; Farrus B; Ballesta AM
Anticancer Res; 2003; 23(2A):1043-50. PubMed ID: 12820345
[TBL] [Abstract][Full Text] [Related]
6. Relationships between circulating hormone levels, mammographic percent density and breast cancer risk factors in postmenopausal women.
Johansson H; Gandini S; Bonanni B; Mariette F; Guerrieri-Gonzaga A; Serrano D; Cassano E; Ramazzotto F; Baglietto L; Sandri MT; Decensi A
Breast Cancer Res Treat; 2008 Mar; 108(1):57-67. PubMed ID: 17468953
[TBL] [Abstract][Full Text] [Related]
7. Endocrine status in stage II vs. advanced premenopausal and postmenopausal breast cancer patients.
Bhatavdekar JM; Patel DD; Shah NG; Giri DD; Vora HH; Karelia NH; Trivedi SN; Ghosh N; Suthar TP
Neoplasma; 1992; 39(1):39-42. PubMed ID: 1388248
[TBL] [Abstract][Full Text] [Related]
8. Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause.
Pujol P; Daures JP; Thezenas S; Guilleux F; Rouanet P; Grenier J
Cancer; 1998 Aug; 83(4):698-705. PubMed ID: 9708933
[TBL] [Abstract][Full Text] [Related]
9. Proliferation measurement in breast cancer by two different methods.
Martínez-Arribas F; Martín-Garabato E; Lafuente P; Tejerina A; Lucas R; Sánchez J; Schneider J
Anticancer Res; 2006; 26(1A):199-202. PubMed ID: 16475699
[TBL] [Abstract][Full Text] [Related]
10. A prospective prognostic study of the hormonal milieu at the time of surgery in premenopausal breast carcinoma.
Pujol P; Daures JP; Brouillet JP; Chang S; Rouanet P; Bringer J; Grenier J; Maudelonde T
Cancer; 2001 May; 91(10):1854-61. PubMed ID: 11346866
[TBL] [Abstract][Full Text] [Related]
11. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer.
Eskelinen M; Kataja V; Hämäläinen E; Kosma VM; Penttilä I; Alhava E
Anticancer Res; 1997; 17(2B):1231-4. PubMed ID: 9137478
[TBL] [Abstract][Full Text] [Related]
12. Serum hormones in human breast cancer subjects.
Krishnamoorthy G; Govindarajulu P; Ramalingam V
Neoplasma; 1989; 36(2):221-31. PubMed ID: 2497392
[TBL] [Abstract][Full Text] [Related]
13. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer.
Lumachi F; Basso SM; Brandes AA; Pagano D; Ermani M
Anticancer Res; 2004; 24(5B):3221-4. PubMed ID: 15510614
[TBL] [Abstract][Full Text] [Related]
14. Bcl-2 expression in breast cancer: a comparative study at the mRNA and protein level.
Martínez-Arribas F; Alvarez T; Del Val G; Martín-Garabato E; Núñez-Villar MJ; Lucas R; Sánchez J; Tejerina A; Schneider J
Anticancer Res; 2007; 27(1A):219-22. PubMed ID: 17352236
[TBL] [Abstract][Full Text] [Related]
15. Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers.
Crosier M; Scott D; Wilson RG; Griffiths CD; May FE; Westley BR
Clin Cancer Res; 1999 Oct; 5(10):2682-8. PubMed ID: 10537329
[TBL] [Abstract][Full Text] [Related]
16. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
17. The importance of prognostic factors in premenopausal women with breast cancer.
Finek J; Holubec L; Topolcan O; Elgrova L; Skalova A; Pecen L
Anticancer Res; 2007; 27(4A):1893-6. PubMed ID: 17649790
[TBL] [Abstract][Full Text] [Related]
18. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women.
Eliassen AH; Missmer SA; Tworoger SS; Spiegelman D; Barbieri RL; Dowsett M; Hankinson SE
J Natl Cancer Inst; 2006 Oct; 98(19):1406-15. PubMed ID: 17018787
[TBL] [Abstract][Full Text] [Related]
19. [Steroid receptor levels in human breast carcinomas in relation to serum hormone levels in postmenopausal patients (author's transl)].
Reiner G; Bieglmayer C; Jakesz R; Kees A; Kolb R; Spona J
Wien Klin Wochenschr; 1981 May; 93(11):339-42. PubMed ID: 6791390
[TBL] [Abstract][Full Text] [Related]
20. Preoperative serum levels of follicle stimulating hormone (FSH) and prognosis in invasive breast cancer.
Eskelinen M; Nordén T; Lindgren A; Wide L; Adami HO; Holmberg L
Eur J Surg Oncol; 2004 Jun; 30(5):495-500. PubMed ID: 15135476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
